HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
25.06.2026
— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —
